查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842012

日本次世代定序市场：市场规模、份额和趋势分析（按技术、产品、应用、工作流程和最终用途划分），细分市场预测（2025-2033 年）

Japan Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology, By Product, By Application, By Workflow, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

日本次世代定序市场预计到 2024 年将达到 3.875 亿美元，从 2024 年到 2033 年的复合年增长率为 17.24%。

推动这一成长的关键因素包括基因定序成本的下降、云端运算和资料整合技术的显着进步等。此外，癌症治疗领域投资的增加以及次世代定序（NGS）在癌症诊断和治疗中的广泛应用，预计也将进一步推动市场扩张。

癌症发生率上升和精准医疗的发展

日本的癌症发生率和死亡率居世界首位，给其医疗体系带来了巨大压力。日益加重的负担使得日本迫切需要先进的诊断工具，以实现早期检测、精准的肿瘤表征和更有效的治疗方案。次世代定序（NGS）已成为实现这一目标的关键技术，它能够对肿瘤进行详细的基因组分析，识别可靶向的突变，并透过液态切片监测疾病进展。 NGS在肿瘤学领域的临床效用正日益受到日本各大医院和癌症研究中心的认可，并逐渐广泛应用于常规癌症诊断。

政府支持的精准医疗计画正透过推动NGS技术融入主流临床实践，进一步加速这一趋势。例如，厚生倡议省设立的癌症基因组医学推进计划等国家级项目，正在全国范围内建立专门的癌症基因组医学中心，确保患者能够公平地获得先进的定序的诊断技术。此外，越来越多的标靶治疗伴随诊断产品获得日本监管机构的核准，进一步推动了NGS技术的临床需求。由于肿瘤学仍然是NGS在日本最大的应用领域，不断上升的癌症发生率以及政府对精准医疗的重视，都成为市场成长的强劲动力。

政府支持政策和基因组计划

日本政府透过创造有利的研究和监管环境，在扩大次世代定序（NGS）技术的应用方面发挥关键作用。诸如日本基因组医学计划和癌症基因组医学推进计划等国家级倡议，为大规模基因组研究投入了大量资金，包括基于人群的基因测序计划和临床癌症基因组研究。这些计画旨在促进学术研究，并建立强大的资料库，为转化医学、生物标记发现和新治疗方法开发奠定基础。透过投资建设癌症基因组定序中心和国家生物样本库等基础设施，日本确保研究人员能够获得高品质的基因组数据，从而加速疾病机制的发现和个人化治疗的研发。

日本的法规结构不断发展完善，旨在支援新一代定序（NGS）技术快速、顺利地融入科学研究和临床工作流程。日本药品和医疗设备管理局（PMDA）已为基于NGS的诊断试剂盒和伴随诊断产品製定了清晰的核准途径，降低了学术界和产业界研究人员开发新型检测方法和平台的门槛。这些扶持政策促进了大学、医院和生技公司之间的合作，建构了一个充满活力的研究生态系统。政府资助、监管支持和科研机构的积极参与，使日本成为全球NGS研究最密集的市场之一，并使其成为亚洲基因组学主导创新中心。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：日本次世代定序市场：影响因素、趋势与范围

  • 市场关联性展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 日本次世代定序市场：分析工具
    • SWOT分析：依因素（政治、法律、经济、技术）进行分析
    • 波特五力分析

第四章：日本次世代定序市场：按技术分類的商业分析

  • 按变异分析和技术分類的次世代定序市场
  • 标靶定序和定序
  • 全基因测序
  • 全EXOME定序

第五章：日本次世代定序市场：按产品分類的业务分析

  • 次世代定序市场：按产品分類的差异分析
  • 平台
  • 消耗品

第六章：日本次世代定序市场：按应用领域分類的业务分析

  • 次世代定序市场：按应用领域分類的变异分析
  • 瘤
  • 临床研究
  • 生殖健康
  • HLA型检测/免疫系统监测
  • 总体基因体学、流行病学和药物研发
  • 农业基因组学与法医学
  • 消费者基因体学

第七章：日本次世代定序市场：基于工作流程的业务分析

  • 按变异分析和工作流程分類的次世代定序市场
  • 定序前
  • 定序
  • 数据分析

第八章：日本次世代定序市场：按最终用途分類的业务分析

  • 次世代定序市场：基于变异分析和最终用途
  • 学术研究
  • 临床研究
  • 医院和诊所
  • 製药和生物技术公司
  • 其他用户

第九章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 主要企业市场分析（2024 年）
  • 市场参与企业概览
    • Illumina, Inc
    • QIAGEN
    • Thermo Fisher Scientific, Inc
    • BGI
    • Pacific Biosciences
    • Bio Rad Laboratories
    • Oxford Nanopore Technologies, Inc
    • Myriad Genetics. Inc.
    • Agilent Technologies, Inc.
    • Eurofins Scientific
Product Code: GVR-4-68040-156-5

Market Size & Trends:

The Japan next-generation sequencing market size was valued at USD 387.5 million in 2024 and is projected to grow at a CAGR of 17.24% from 2024 to 2033. Key drivers of this growth include the declining costs associated with genetic sequencing and significant advancements in cloud computing and data integration technologies. Moreover, rising investments in cancer treatment and the broad application of next-generation sequencing (NGS) in cancer diagnosis and therapy are expected to propel market expansion further.

Rising Cancer Burden & Precision Medicine Initiatives

Japan faces some of the highest cancer rates and death rates worldwide, which continue to put a lot of pressure on its healthcare system. This increasing burden creates a strong need for advanced diagnostic tools that allow early detection, accurate characterizations of tumors, and improved treatment choices. Next-generation sequencing (NGS) has become a key technology in this effort, as it enables detailed genomic profiling of tumors, identification of actionable mutations, and monitoring of disease progression through liquid biopsies. The clinical usefulness of NGS in oncology is gaining recognition across Japan's hospitals and cancer research centers, leading to broader adoption in routine cancer diagnostics.

Government-backed precision medicine initiatives further accelerate this trend by promoting the integration of NGS into mainstream clinical practice. National programs like the Cancer Genomic Medicine Program, established by Japan's Ministry of Health, Labour and Welfare, have appointed specialized cancer genome medical centers across the country, ensuring equitable access to advanced sequencing-based diagnostics. Additionally, companion diagnostics for targeted therapies are increasingly gaining approval from Japan's regulatory authorities, which boosts the clinical demand for NGS technologies. Since oncology remains the largest application area for NGS in Japan, the combined effect of rising cancer rates and supportive government precision medicine efforts is a strong driver of market growth.

Supportive Government Policies & Genomic Programs

The Japanese government has played a key role in increasing the use of next-generation sequencing (NGS) technologies by creating a supportive research and regulatory environment. National initiatives like the Japan Genomic Medicine Program and the Cancer Genomic Medicine Promotion Plan have allocated significant funding for large-scale genomic research, including population-based genome sequencing projects and clinical cancer genome studies. These programs aim to boost academic research and develop strong databases that form the basis for translational medicine, biomarker discovery, and new therapeutic development. By investing in infrastructure such as cancer genome sequencing centers and national biobanks, Japan enables researchers to access high-quality genomic data that speed up discoveries in disease mechanisms and personalized treatments.

The country's regulatory framework has progressed to support faster and smoother integration of NGS into research and clinical workflows. The Pharmaceuticals and Medical Devices Agency (PMDA) has established clear approval pathways for NGS-based diagnostic panels and companion diagnostics, lowering barriers for academic groups and industry researchers to develop new assays and platforms. These supportive policies foster collaborations among universities, hospitals, and biotechnology companies, creating a thriving research ecosystem. The alignment of government funding, regulatory support, and institutional participation makes Japan one of the most research-intensive markets for NGS worldwide, establishing it as a hub for genomics-driven innovation in Asia.

Japan Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the Japan next generation sequencing market on the basis of technology, product, end use, workflow, and application:

  • Technology Outlook (Revenue in USD Million, 2021 - 2033)
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing
    • DNA-based
    • RNA-based
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Consumables
    • Sample Preparation
    • Target Enrichment
  • Platforms
    • Sequencing
    • Data Analysis
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
    • Diagnostics and Screening
    • Oncology Screening
    • Sporadic Cancer
    • Inherited Cancer
    • Companion Diagnostics
    • Other Diagnostics
    • Research Studies
  • Clinical Investigation
    • Infectious Diseases
    • Inherited Diseases
    • Idiopathic Diseases
    • Non-Communicable/Other Diseases
  • Reproductive Health
    • NIPT
    • Aneuploidy
    • Microdeletions
    • PGT
    • Newborn Genetic Screening
    • Single Gene Analysis
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics
  • Consumer Genomics
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-Sequencing
    • Nucleic Acid Extraction
    • Library Preparation
  • Sequencing
  • NGS Data Analysis
    • NGS Primary Data Analysis
    • NGS Secondary Data Analysis
    • NGS Tertiary Data Analysis
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other users

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Technology
    • 1.1.2. Product
    • 1.1.3. Application
    • 1.1.4. Workflow
    • 1.1.5. End Use
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights

Chapter 3. Japan Next Generation Sequencing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising cancer burden & precision medicine initiatives
      • 3.2.1.2. Supportive government policies & genomic programs
      • 3.2.1.3. Rise in competition among prominent market entities
      • 3.2.1.4. Rising clinical opportunity for NGS technology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of computational efficiency for data management
      • 3.2.2.2. Non-value-based NGS reimbursement policy and regulation status
      • 3.2.2.3. Challenges associated with NGS implementation.
  • 3.3. Japan Next Generation Sequencing Market Analysis Tools
    • 3.3.1. SWOT analysis; by factor (political & legal, economic, and technological)
    • 3.3.2. Porter's Five Forces Analysis

Chapter 4. Japan Next Generation Sequencing Market: Technology Business Analysis

  • 4.1. Next Generation Sequencing Market: Technology Movement Analysis
  • 4.2. Targeted Sequencing & Resequencing
    • 4.2.1. Targeted Sequencing & Resequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 4.2.1.1. DNA-based targeted sequencing & resequencing
        • 4.2.1.1.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
      • 4.2.1.2. RNA-based targeted sequencing & resequencing
        • 4.2.1.2.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 5. Japan Next Generation Sequencing Market: Product Business Analysis

  • 5.1. Next Generation Sequencing Market: Product Movement Analysis
  • 5.2. Platforms
    • 5.2.1. Platforms Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 5.2.1.1. Sequencing
        • 5.2.1.1.1. Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
      • 5.2.1.2. Data Analysis
        • 5.2.1.2.1. Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million
  • 5.3. Consumables
    • 5.3.1. Consumables market estimates and forecast, 2021 - 2033 (USD million)
    • 5.3.2. Sample Preparation
      • 5.3.2.1. Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.3. Target Enrichment
      • 5.3.3.1. Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. Japan Next Generation Sequencing Market: Application Business Analysis

  • 6.1. Next Generation Sequencing Market: Application Movement Analysis
  • 6.2. Oncology
    • 6.2.1. Oncology Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.2.2. Diagnostics & Screening
      • 6.2.2.1. Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.2. Oncology screening
        • 6.2.2.2.1. Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.2. Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.3. Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.3. Companion diagnostics
        • 6.2.2.3.1. Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.4. Other diagnostics
        • 6.2.2.4.1. Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.2.3. Research Studies
      • 6.2.3.1. Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3. Clinical investigation
    • 6.3.1. Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.2. Infectious Diseases
      • 6.3.2.1. Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.3. Idiopathic Diseases
      • 6.3.3.1. Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.4. Inherited Diseases
      • 6.3.4.1. Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.5. Non-Communicable/Other Diseases
      • 6.3.5.1. Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4. Reproductive Health
    • 6.4.1. Reproductive Health Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.4.2. NIPT
      • 6.4.2.1. NIPT market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.2. Aneuploidy
        • 6.4.2.2.1. Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.3. Microdeletions
        • 6.4.2.3.1. Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.3. PGT
      • 6.4.3.1. PGT market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.4. Newborn Genetic Screening
      • 6.4.4.1. Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.5. Single Gene Analysis
      • 6.4.5.1. Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5. HLA Typing/Immune System Monitoring
    • 6.5.1. HLA Typing/Immune System Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.6. Metagenomics, Epidemiology & Drug Development
    • 6.6.1. Metagenomics, Epidemiology & Drug Development Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.7. Agrigenomics & Forensics
    • 6.7.1. Agrigenomics & Forensics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.8. Consumer Genomics
    • 6.8.1. Consumer Genomics Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7. Japan Next Generation Sequencing Market: Workflow Business Analysis

  • 7.1. Next Generation Sequencing Market: Workflow Movement Analysis
  • 7.2. Presequencing
    • 7.2.1. Pre-Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 7.2.1.1. Nucleic Acid Extraction
        • 7.2.1.1.1. Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
      • 7.2.1.2. Library Preparation
        • 7.2.1.2.1. Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3. Sequencing
    • 7.3.1. Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.4. Data Analysis
    • 7.4.1. Data Analysis Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.4.2. Primary Data NGS Analysis
      • 7.4.2.1. Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.3. Secondary Data Analysis
      • 7.4.3.1. Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.4. Tertiary Data Analysis
      • 7.4.4.1. Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. Japan Next Generation Sequencing Market: End Use Business Analysis

  • 8.1. Next Generation Sequencing Market: End Use Movement Analysis
  • 8.2. Academic Research
    • 8.2.1. Academic Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.3. Clinical Research
    • 8.3.1. Clinical Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.4. Hospitals & Clinics
    • 8.4.1. Hospitals & Clinics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.5. Pharmaceutical & Biotech Entities
    • 8.5.1. Pharmaceutical & Biotech Entities Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.6. Other Users
    • 8.6.1. Other Users Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Key Company Market Position Analysis, 2024
  • 9.4. Participants Overview
    • 9.4.1. Illumina, Inc
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. QIAGEN
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Thermo Fisher Scientific, Inc
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. BGI
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Pacific Biosciences
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Bio Rad Laboratories
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Oxford Nanopore Technologies, Inc
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Myriad Genetics. Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Agilent Technologies, Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Eurofins Scientific
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Japan next generation sequencing market, by technology, 2021 - 2033 (USD Million)
  • Table 4 Japan next generation sequencing market, by product, 2021 - 2033 (USD Million)
  • Table 5 Japan next generation sequencing market, by application, 2021 - 2033 (USD Million)
  • Table 6 Japan next generation sequencing market, by workflow, 2021 - 2033 (USD Million)
  • Table 7 Japan next generation sequencing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Japan next generation sequencing market: market outlook
  • Fig. 7 Japan next generation sequencing competitive insights.
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Japan next generation sequencing market driver impact
  • Fig. 11 Japan next generation sequencing market restraint impact
  • Fig. 12 Japan next generation sequencing market: Technology movement analysis
  • Fig. 13 Japan next generation sequencing market: Technology outlook and key takeaways
  • Fig. 14 Targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 15 DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Whole genome sequencing market estimates and forecast, 2021-2033 (USD Million)
  • Fig. 18 Whole exome sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Japan Next-generation sequencing market: Product outlook key takeaways
  • Fig. 20 Japan Next-generation sequencing market: Product movement analysis
  • Fig. 21 Platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Consumables market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Japan next generation sequencing Market: Application Movement Analysis
  • Fig. 29 Japan next generation sequencing market: Application outlook and key takeaways
  • Fig. 30 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Reproductive health market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 NIPT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 PGT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 49 Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 HLA typing/immune system monitoring market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Metagenomics, epidemiology & drug development market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Agrigenomics & forensics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Consumer genomics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Japan next generation sequencing market: workflow movement analysis
  • Fig. 55 Japan next generation sequencing market: workflow outlook and key takeaways
  • Fig. 56 Pre-sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 59 Sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 Japan Next generation sequencing market End Use outlook key takeaways
  • Fig. 65 Japan Next-generation sequencing market: End Use movement analysis
  • Fig. 66 Academic research market estimates and forecast, 2021 - 2033 (USD Million))
  • Fig. 67 Clinical research market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Hospitals & clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 69 Pharmaceutical & biotech entities market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Other users market estimates and forecast, 2021 - 2033 (USD Million)